These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24903767)

  • 21. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review: colitis associated with anti-CTLA-4 therapy.
    Gupta A; De Felice KM; Loftus EV; Khanna S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
    Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
    Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.
    Wilgenhof S; Morlion V; Seghers AC; Du Four S; Vanderlinden E; Hanon S; Vandenbroucke F; Everaert H; Neyns B
    Anticancer Res; 2012 Apr; 32(4):1355-9. PubMed ID: 22493370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
    Buchbinder EI; McDermott DF
    Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
    Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
    Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
    Kopecký J; Trojanová P; Kubeček O; Kopecký O
    Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
    JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
    Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
    Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
    Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
    Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
    Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C; Mateus C
    Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.